DKDarina V. Kiseleva

Darina V. Kiseleva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Darina V. Kiseleva has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Department of Medical Sciences of the RAS, Therapeutic Sciences Council meeting: Scientific projects marathon of Russian therapeutic departments "From innovative technologies and education to healthcare practice. Pulmonology: from real clinical practice to promising developments"

    by O. M. Drapkina, S. N. Avdeev, E. K. Beltyukov, V. V. Naumova, D. V. Kiseleva, А. В. Будневский, E. S. Ovsyannikov, С. Н. Фейгельман, R. E. Tokmachev, E. V. Garbuzova, et al.

    Заседание Совета по терапевтическим наукам Отделения медицинских наук РАН: Марафон научных проектов терапевтических кафедр России "От инновационных технологий и образования к практике здравоохранения. Пульмонология: от реалий клинической практики к перспективным разработкам"

  • Open Access

    Registry as a tool for monitoring effectiveness of immunobiological therapy for severe asthma in real clinical practice

    by V. V. Naumova, D. V. Kiseleva, K. A. Zykov, Е. К. Beltyukov, E. S. Klyachina, I. O. Nikiforova, P. A. Suvorkov

    Registry is a unique and universal mechanism for group and individual approaches to managing patients, including those with severe asthma (SA) who require targeted therapy.The aim is to evaluate the clinical and organizational potential of the SA patient registry as a tool for group and individual approaches to patient management, as a way to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitoring immunobiological therapy (using anti-IgE therapy as an example) in patients with SA in Sverdlovsk region.Methods. The subject of the study was the Territorial Registry of Patients with SA of the Sverdlovsk region. The registry effectiveness was assessed based on the clinical and organizational indicators, including monitoring the effectiveness of 3-year anti-IgE therapy in patients with SA with an allergic component.Results. From 2016 to 2023, both inclusive, 198 patients with SA were entered into the registry. Analysis of the registry data allowed us to develop a scheme for SA phenotyping and selecting the 1st and 2nd line targeted drugs and a scheme for phenotyping and selecting a targeted drug for T2 inflammatory nasal diseases. Over 3 years of anti-IgE therapy with omalizumab, the ACT test increased from 9.00 to 19.50 points, the proportion of patients with partial and good asthma control increased by 13.89 times, the frequency of exacerbations decreased by 71.43%, FEV1 increased by 17.91%, and the proportion of patients requiring systemic corticosteroids decreased by 83.32%.Conclusion. The registry of SA patients has high clinical and organizational potential to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitor the effectiveness and safety of immunobiological therapy. The 3-year anti-IgE therapy demonstrates statistically significant effectiveness in patients with SA with an allergic component.

  • Open Access

    Targeted Therapy for Severe Asthma: Switching Biological agents in Real Clinical Practice — Causes and Consequences

    by Veronika V. Naumova, Evgeny K. Beltyukov, Darina V. Kiseleva, Galina A. Bykova, Olga G. Smolenskaya, Alexandra A. Shtanova, Daria А. Stepina, Бельтюков Евгений Кронидович

    BACKGROUND: The complexity of choosing a genetically engineered biological drug for the treatment of severe bronchial asthma is due to the intersection of disease endotypes and phenotypes. Mistakes in biological choice lead to the discontinuation and/or switching of the drug because of insufficient effectiveness of therapy. AIM: To determine the reasons for stopping targeted therapy and biological switching effectiveness in patients with severe bronchial asthma in clinical practice. MATERIALS AND METHODS: Patients with severe bronchial asthma (n=116) from the Sverdlovsk region register were divided into three groups: (1) continuous, (2) stoppers, and (3) switchers. Predictors of biological withdrawal and switching, reasons for the first biological stopping, switching schemes, therapy effectiveness after switching according to the asthma control test (ACT), asthma quality of life questionnaire (AQLQ), 22-item sinonasal outcome test [SNOT-22], forced expiratory volume in the first second, need for systemic glucocorticosteroids, and achievement of strong asthma control were determined. RESULTS: Of the 116 patients in the registry, 17.2% were stoppers and 12.1% were switchers. Stoppers suffered from chronic rhinosinusitis with nasal polyps less often and had an earlier asthma onset. Switchers had higher blood eosinophil levels. Therapy was canceled for personal reasons in 45% of the patients. The ineffectiveness of therapy in severe bronchial asthma and/or chronic rhinosinusitis with nasal polyps was the main reason for switching (92.8%) from omalizumab and benralizumab. The drug of choice for switching was dupilumab. Indicators improved, namely, ACT by 86.4%, AQLQ by 52.5%, SNOT-22 by 48%, and forced expiratory volume in the first second by 21.2%), and the need for systemic glucocorticosteroids decreased to 0 in 12 months after switching. Strong control was achieved in 62.5% of the patients when excluding the forced expiratory volume in the first second, and 50% of patients when including the forced expiratory volume in the first second. CONCLUSION: Careful selection of targeted therapy patients minimizes the failures of the starting drug to 12.1%. Switching the starting genetically engineered biological drug, aimed only at blocking eosinophils or only at blocking IgE, because of its inefficiency, to a drug with a dual mechanism of action leads to a significant improvement in ACT, AQLQ, SNOT-22, forced expiratory volume in the first second, and absence of systemic glucocorticosteroids.


  • Open Access

    Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract

    by V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova, D. A. Stepina

    T2 inflammation underlies diseases such as bronchial asthma, allergic rhinitis and chronic rhinosinusitis with nasal polyps. These diseases often have a severe course and often accompany each other, which leads to a significant decrease in the quality of life of patients. Studying the mechanisms of inflammation at the molecular level has made it possible to develop immunobiological drugs aimed at different stages of pathogenesis. One of the targets of immunobiological therapy for T2 inflammation, which can be affected by monoclonal antibodies, is immunoglobulin E. The purpose of the scientific review is to summarize the data accumulated over the past 25 years from randomized clinical trials and studies of real clinical practice on the effectiveness and safety of the original anti-IgE drug – “omalizumab”, including in comorbid patients. Clinical trials have shown that the use of omalizumab in patients with severe bronchial asthma reduces the frequency of exacerbations and severe exacerbations of asthma, reduces the number of hospitalizations and emergency room visits due to asthma exacerbations, reduces oral and inhaled glucocorticosteroids doses, improves respiratory function and improves quality of life. Omalizumab reduces the severity of nasal and ocular symptoms and reduces the need for antihistamines in patients with severe allergic rhinitis. Omalizumab effectiveness in patients with chronic rhinosinusitis with nasal polyps is manifested by decrease in nasal symptoms (nasal congestion, rhinorrhea), improvement in the sense of smell, decrease in polyps size, and the need for systemic glucocorticosteroids and surgical interventions. Omalizumab showed good tolerability and safety profile comparable to placebo in both clinical trials and routine practice.

  • Open Access

    Anti-IL-4,13 strategy in management of comormid patients in the regional register of severe bronchial asthma

    by Veronika V. Naumova, Darina V. Kiseleva, Evgeny K. Beltyukov, Yana R. Starikova, Бельтюков Евгений Кронидович

    BACKGROUND: T2 inflammation underlies bronchial asthma and inflammatory nasal diseases, supporting the concept of a united airway disease. Dupilumab, by blocking interleukin-4 and -13 receptors, can improve the clinical and functional parameters and life quality of comorbid patients with T2 diseases. AIM: To evaluate efficacy of anti-IL4R,13 therapy in patients with severe asthma with chronic inflammatory nasal diseases in real clinical practice. MATERIALS AND METHODS: The study of dupilumab efficacy was conducted by comparing related populations based on a regional register of patients with severe asthma and concomitant chronic inflammatory nasal diseases. Asthma control achievement and decrease in the rate of patients with uncontrolled asthma were assessed as primary endpoint. The need for bronchodilators and systemic glucocorticosteroids, number of asthma exacerbations, emergency calls and hospitalizations, AQLQ scores, level of peripheral blood eosinophils, and respiratory function were also assessed. Nasal symptoms were assessed using SNOT-22 and VAS. A subgroup analysis of ACT scores was performed depending on chronic inflammatory nasal disease phenotypes. RESULTS: Within 12 months of dupilumab therapy, ACT increased from 11 (Q1Q3: 713) to 20 (Q1Q3: 1824) points (p 0.001). The rate of patients with partially and fully controlled asthma increased from 0 to 57.9% (p 0.001). The need for bronchodilators decreased from 17.5 doses per week (Q1Q3: 5.824.5) to 1.0 (Q1Q3: 0.02.2) (p 0.001). Before the dupilumab therapy, 68.5% of the patients took systemic corticosteroids and, after 12 months, 10.5% of patients (p 0.001). The number of asthma exacerbations decreased from 2.191.83 (95% CI 1.283.11) to 0.220.55 (0.050.49) (p 0.001) and hospitalizations from 1.001.27 (95% CI 0.371.63) to 0.170.51 (95% CI 0.090.42) (p 0.001). AQLQ scores increased from 2.91 (Q1Q3: 2.433.86) to 5.89 points (Q1Q3: 4.706.58) (p 0.001). The volume of forced exhalation in 1 sec increased from 55.38%16.66% (95% CI 47.1063.67) to 81.5%19.14% (95% CI 71.9891.02) (p 0.001). SNOT-22 scores decreased from 4729 (95% CI 3461) to 2518 (95% CI 1734) points (p 0.001) and the VAS score from 72 (95% CI 68) to 42 (95% CI 35) (p 0.001). CONCLUSIONS: Dupilumab improved asthma and nasal symptoms control, improved quality of life and respiratory function, and reduce asthma exacerbations and hospitalizations. Patients with severe asthma and comorbid allergic rhinitis and chronic rhinosinusitis with polyps responded better to dupilumab therapy than patients with chronic rhinosinusitis without polyps.


  • Open Access

    Сlinical and allergological characteristics of chronic inflammatory diseases of the nose in patients with severe bronchial asthma receiving immunobiological therapy in the Sverdlovsk region

    by D. V. Kiseleva, E. K. Beltyukov, V. V. Naumova

    Introduction. Allergic rhinitis, chronic rhinosinusitis (with/without polyps) are chronic inflammatory diseases of the nose and often accompany asthma, aggravating its severity.Aim of the study. Тo determine the phenotypes, spectrum of sensitization and severity of chronic inflammatory diseases of the nose in patients with severe bronchial asthma receiving immunobiological therapy in the Sverdlovsk region.Materials and methods. The territorial register of adult patients with severe bronchial asthma (n = 85) who received immunobiological therapy in the Sverdlovsk region in October 2021 was analyzed. When diagnosing chronic inflammatory diseases of the nose, an examination by an otorhinolaryngologist and computed tomography of the paranasal sinuses were performed; were determined: the absolute number of blood eosinophils, specific IgE to inhaled allergens, including the FadiatopTM method; skin tests were performed; assessment of the severity of nasal symptoms was determined using the SNOT-22, VAS.Results. Chronic inflammatory diseases of the nose were reported in 89.4% of patients. Allergic rhinitis occurred in 54.1% of cases (n = 46). 54.3% (n = 25) were dominated by patients with a moderate course; severe course was observed in 28.3% of cases (n = 13). Allergic rhinitis in 92.3% of cases (n = 36) was accompanied by allergic asthma and in 71.4% (n = 10) – mixed. Sensitization to household allergens was more common, from seasonal allergens to tree pollen. Phadiatop was positive in all patients with allergic rhinitis and negative in patients with chronic rhinosinusitis with/without nasal polyps. Patients with chronic rhinosinusitis occurred in 35.3% of cases (n=30); nasal polyps were in 23.5% (n = 20). The highest rates of blood eosinophilia were in patients with concomitant chronic rhinosinusitis with nasal polyps – 920 cells/µl. This phenotype in 95% of cases was accompanied by non-allergic (eosinophilic) asthma.Conclusion. Severe bronchial asthma is almost always accompanied by chronic inflammatory diseases of the nose. Phadiatop shows its high informativeness in determining the phenotype of allergic rhinitis.


  • The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice

    by Darina V. Kiseleva, Evgeny K. Beltyukov, Veronika V. Naumova, Бельтюков Евгений Кронидович

    BACKGROUND: Omalizumab, by binding immunoglobulin (Ig) E in patients with atopic asthma, can improve clinical and functional parameters and patients quality of life. AIM: To evaluate the efficacy of anti-IgE therapy in patients with allergic rhinitis treated with omalizumab for concomitant severe atopic asthma in real clinical practice MATERIALS AND METHODS: This open, non-interventional, prospective, and non-randomized study in real clinical practice was conducted in the Sverdlovsk region in October 2021 based on a regional registry of adult patients with severe asthma with chronic nasal inflammatory diseases and receiving targeted therapy. Dynamics of nasal symptoms were assessed using the Sino-nasal-outcome test 22 (SNOT-22) questionnaire and visual analog scale (VAS) initially and after 4 and 12 months of omalizumab therapy. Peripheral blood eosinophil level was assessed before and after 4 months of omalizumab therapy. RESULTS: The study included 26 patients. Assessment of nasal symptoms dynamics using the SNOT-22 questionnaire at baseline and after 4 months of omalizumab therapy revealed a decreased severity of symptoms (p 0.001) of 46.8522.04 points at baseline (95% confidence interval [CI]: 37.9455.75) and 30.6514.81 points after 4 months (95% CI: 24.6736.64). Additionally, improvement in SNOT-22 questionnaire score was revealed in 18 patients treated with omalizumab during 12 months, with 47.5 points before therapy (Q₁Q₃: 35.759.3), 30.4 points after 4 months (Q₁Q₃: 22.138.1), and 24.9 points after 12 months (Q₁Q₃: 16.932.9) (p=0.001). Improvement in rhinitis symptoms control was observed according to the VAS scale, with 8.0 points before therapy (Q₁Q₃: 6.29.0), 5.0 points after 4 months (Q₁Q₃: 3.25.8), and 5.0 points after 12 months of treatment (Q₁Q₃: 4.06.8). The eosinophil levels (n=16) decreased from 510.9317.9 cells/l (95% CI: 341.5680.3) to 327.4217.7 cells/l (95% CI: 211.4443.5) after 4 months of anti-IgE therapy (p 0.041). CONCLUSIONS: Omalizumab in real clinical practice has demonstrated improvement of rhinitis symptoms and quality of life in patients with allergic rhinitis with concomitant severe atopic asthma. Additionally, a statistically significant decrease in peripheral blood eosinophils level was observed, which largely determines airway inflammation severity and clinical manifestations of allergic rhinitis and bronchial asthma.

  • Open Access

    Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma

    by Veronika Naumova, Evgeny Beltyukov, Katarzyna Niespodziana, Peter Errhalt, Rudolf Valenta, Alexander Karaulov, Darina Kiseleva

    Molecular therapies, including anti-IgE, biologicals and small molecules are increasingly used for treatment of asthma. The effectiveness of these therapies may be increased with biomarkers. Aim of this study was to assess the value of measuring cumulative IgE levels specific for respiratory allergens to increase the efficacy of anti-IgE therapy for severe bronchial asthma. One hundred and thirty seven patients with severe asthma were recruited from 2016 to 2022. Standard empirical allergy diagnosis (i.e., anamnesis, skin testing, allergen-specific IgE measurement), blood eosinophil counting, measurement of total IgE and of cumulative IgE-specific for respiratory allergens by Phadiatop™ were performed. Thirty four patients with severe allergic asthma, for whom all three diagnostic methods were performed, were then used to analyze the efficacy of anti-IgE treatment in patients stratified in two groups according to cumulative IgE levels specific for respiratory allergens determined by Phadiatop™. Group #1 patients (n = 8) had cumulative specific IgE values ≥ 0.35 and < 1.53 PAU/l while in group #2 patients (n = 26) they were ≥ 1.53 PAU/l. Treatment with Omalizumab was performed for at least 12 months. The level of asthma control (ACT questionnaire), the number of asthma exacerbations, the quality of life (AQLQ questionnaire), the need for systemic corticosteroids, and the respiratory function (FEV1) was determined by “before-after” analysis for each group, followed by a comparison of the dynamics between groups. In group 2 patients with an initial allergen-specific IgE level ≥ 1.53 kUA/L, the efficacy of Omalizumab treatment was better regarding asthma control, number of exacerbations, and quality of life than in group 1 patients. Our study provides evidence that measuring cumulative levels of IgE specific for respiratory allergens could be a useful screening method for detecting an allergic phenotype of severe asthma and may serve as biomarker to enhance the success of IgE-targeted therapy.


  • Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice

    by Veronika Naumova, Evgeny Beltyukov, Darina Kiseleva, Бельтюков Евгений Кронидович

    BACKGROUND. T2 inflammation underlies non-allergic eosinophilic severe bronchial asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Existing targeted anti-IL-5 drugs can improve clinical and functional parameters in patients with a combination of severe asthma and CRSwNP. AIM: to evaluate mepolizumab efficacy in patients with non-allergic severe asthma and concomitant inflammatory nasal diseases (CIND) in real clinical practice. MATERIALS AND METHODS. The study was conducted without a control group, by comparing related populations (before-after analysis) and based on the Sverdlovsk regional register of adult patients with severe asthma and CIND. The primary endpoint was asthma control achievement (ACT questionnaire) and decrease in the proportion of patients with uncontrolled severe asthma. The number of asthma exacerbations, emergency calls and hospitalizations, quality of life according to AQLQ questionnaire, peripheral blood eosinophils level and respiratory function (FEV1, FVC, FEV1/FVC) were also assessed. Dynamics of nasal symptoms was assessed using SNOT22 questionnaire and visual analogue scale (VAS). RESULTS. During 12 months of therapy with mepolizumab, ACT increased from 9 (Q1-Q3: 7-11) to 22 points (Q1-Q3: 21-24) (p0.001). The proportion of patients with uncontrolled asthma decreased from 100% to 10% (p0.001). The number of asthma exacerbations decreased from 3.182.8 per patient per year to 0 (p0.001) and hospitalizations from 0.570.9 per patient per year to 0 (p=0.007). Quality of life according to AQLQ increased from 3.481.05 (95% CI 2.734.24) to 5.590.88 (95% CI 4.966.22) points (p0.001). The number of blood eosinophils decreased from 442 (Q1-Q3: 336-853) to 90 (Q1-Q3: 73-117) cells/l (p0.001). There was increase in FEV1 from 63.9%24.2 (95% CI 46.681.2) to 80.5%18.3 (95% CI 67.493.6) (p=0.015). There was decrease in SNOT22 questionnaire score by 33 points (from 4530 to 2215) (p=0.006) and decrease in VAS score by 5 points (from 8 (Q1-Q3: 5-8) to 3 (Q1-Q3: 3-5)) (p=0.017). CONCLUSIONS. According to the study results, there were asthma control improvement, asthma exacerbations decrease, quality of life improvement according to AQLQ. Statistically significant peripheral blood eosinophils decrease and respiratory function improvement were also revealed. In patients with CIND, significant improvement in nasal breathing was noted, which was confirmed by scores of SNOT22 and VAS questionnaires.